Plasma von Willebrand factor as a predictor of survival in pulmonary arterial hypertension associated with congenital heart disease

Brazilian Journal of Medical and Biological Research

Volumn 44, Issue 12, 2011, Pages 1269-1275

  Lopes, A A ^a   Barreto, A C ^a   Maeda, N Y ^b   Cicero C ^a   Soares, R P S ^b   Bydlowski, S P ^a   Rich, S ^c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FUNDAÇÃO PRÓ SANGUE HEMOCENTRO DE SÃO PAULO   (Brazil)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Congenital heart disease; Eisenmenger syndrome; Endothelial dysfunction; Pulmonary hypertension; Th2 cytokine response; Von Willebrand factor

Indexed keywords

BIOLOGICAL MARKER; BOSENTAN; C REACTIVE PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR; ROSUVASTATIN; SILDENAFIL; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; VON WILLEBRAND FACTOR; WARFARIN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONGENITAL HEART DISEASE; CONGENITAL HEART DISEASE ASSOCIATED PULMONARY ARTERIAL HYPERTENSION; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOKINE RESPONSE; DEATH; DISEASE ASSOCIATION; DISEASE SEVERITY; EISENMENGER COMPLEX; FEMALE; FOLLOW UP; GREAT VESSELS TRANSPOSITION; HEART ATRIUM SEPTUM DEFECT; HEART RIGHT VENTRICLE DOUBLE OUTLET; HEART SINGLE VENTRICLE; HEART VENTRICLE SEPTUM DEFECT; HEMATOCRIT; HUMAN; INFLAMMATION; LUNG ARTERY PRESSURE; MALE; OXYGEN TENSION; PATENT DUCTUS ARTERIOSUS; PREDICTION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SURVIVAL; SURVIVAL TIME; SYSTOLIC BLOOD PRESSURE; TH2 CELL; TREATMENT RESPONSE; WALKING;

EID: 82355184020     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2011007500149     Document Type: Article

References (40)

1. Blyth KG, Groenning BA, Mark PB, Martin TN, Foster JE, Steedman T, et al. NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension. Eur Respir J 2007; 29: 737-744.
2. Nagaya N, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Nakanishi N, et al. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med 1999; 160: 487-492.
3. Oya H, Nagaya N, Satoh T, Sakamaki F, Kyotani S, Fujita M, et al. Haemodynamic correlates and prognostic signifcance of serum uric acid in adult patients with Eisenmenger syndrome. Heart 2000; 84: 53-58.
4. Rubens C, Ewert R, Halank M, Wensel R, Orzechowski HD, Schultheiss H P, et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001; 120: 1562-1569.
5. Shitrit D, Bendayan D, Bar-Gil-Shitrit A, Huerta M, Rudensky B, Fink G, et al. Signifcance of a plasma D-dimer test in patients with primary pulmonary hypertension. Chest 2002; 122: 1674-1678.
6. Lopes AA, Maeda NY, Goncalves RC, Bydlowski SP. En-dothelial cell dysfunction correlates differentially with survival in primary and secondary pulmonary hypertension. Am Heart J 2000; 139: 618-623.
7. Kawut SM, Horn EM, Berekashvili KK, Widlitz AC, Rosen-zweig EB, Barst RJ. von Willebrand factor independently predicts long-term survival in patients with pulmonary arterial hypertension. Chest 2005; 128: 2355-2362.
8. Barreto AC, Maeda NY, Soares RP, Cicero C, Lopes AA. Rosuvastatin and vascular dysfunction markers in pulmonary arterial hypertension: a placebo-controlled study. Braz J Med Biol Res 2008; 41: 657-663.
9. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-117.
10. Masuyama T, Kodama K, Kitabatake A, Sato H, Nanto S, Inoue M. Continuous-wave Doppler echocardiographic detection of pulmonary regurgitation and its application to noninvasive estimation of pulmonary artery pressure. Circulation 1986; 74: 484-492.
11. Borgeson DD, Seward JB, Miller FA Jr, Oh JK, Tajik AJ. Frequency of Doppler measurable pulmonary artery pressures. J Am Soc Echocardiogr 1996; 9: 832-837.
12. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation 2004; 109: 159-165.
13. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327: 70-75.
14. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159: 1925-1932.
15. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333: 214-221.
16. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732-1739.
17. Sakamaki F, Kyotani S, Nagaya N, Sato N, Oya H, Satoh T, et al. Increased plasma P-selectin and decreased thrombo-modulin in pulmonary arterial hypertension were improved by continuous prostacyclin therapy. Circulation 2000; 102: 2720-2725.
18. White RJ, Meoli DF, Swarthout RF, Kallop DY, Galaria II, Harvey JL, et al. Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2007; 293: L583-L590.
19. Bull TM, Golpon H, Hebbel RP, Solovey A, Cool CD, Tuder RM, et al. Circulating endothelial cells in pulmonary hypertension. Thromb Haemost 2003; 90: 698-703.
20. Diller GP, van Eijl S, Okonko DO, Howard LS, Ali O, Thum T, et al. Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. Circulation 2008; 117: 3020-3030.
21. Friedman R, Mears JG, Barst RJ. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 1997; 96: 2782-2784.
22. Uchiyama T, Kurabayashi M, Ohyama Y, Utsugi T, Akuzawa N, Sato M, et al. Hypoxia induces transcription of the plasmi-nogen activator inhibitor-1 gene through genistein-sensitive tyrosine kinase pathways in vascular endothelial cells. Arte-rioscler Thromb Vasc Biol 2000; 20: 1155-1161.
23. Pinsky DJ, Naka Y, Liao H, Oz MC, Wagner DD, Mayadas TN, et al. Hypoxia-induced exocytosis of endothelial cell Weibel-Palade bodies. A mechanism for rapid neutrophil recruitment after cardiac preservation. J Clin Invest 1996; 97: 493-500.
24. Pinto RF, Higuchi ML, Aiello VD. Decreased numbers of T-lymphocytes and predominance of recently recruited macrophages in the walls of peripheral pulmonary arteries from 26 patients with pulmonary hypertension secondary to congenital cardiac shunts. Cardiovasc Pathol 2004; 13: 268-275.
25. Daley E, Emson C, Guignabert C, de Waal MR, Louten J, Kurup V P, et al. Pulmonary arterial remodeling induced by a Th2 immune response. J Exp Med 2008; 205: 361-372.
26. Rabinovitch M, Andrew M, Thom H, Trusler GA, Williams WG, Rowe RD, et al. Abnormal endothelial factor VIII associated with pulmonary hypertension and congenital heart defects. Circulation 1987; 76: 1043-1052.
27. Rubin DB, Wiener-Kronish JP, Murray JF, Green DR, Turner J, Luce JM, et al. Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmonary sepsis syndrome. J Clin Invest 1990; 86: 474-480.
28. Takahashi H, Ito S, Hanano M, Wada K, Niwano H, Seki Y, et al. Circulating thrombomodulin as a novel endothelial cell marker: comparison of its behavior with von Willebrand factor and tissue-type plasminogen activator. Am J Hematol 1992; 41: 32-39.
29. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chamb-less LE. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997; 96: 1102-1108.
30. Morange PE, Simon C, Alessi MC, Luc G, Arveiler D, Ferri-eres J, et al. Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation 2004; 109: 1343-1348.
31. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Tracy R P, Aleksic N, et al. Coagulation factors, infammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med 2002; 113: 636-642.
32. Ware LB, Conner ER, Matthay MA. von Willebrand factor antigen is an independent marker of poor outcome in patients with early acute lung injury. Crit Care Med 2001; 29: 2325-2331.
33. Gorlach A, BelAiba RS, Hess J, Kietzmann T. Thrombin activates the p21-activated kinase in pulmonary artery smooth muscle cells. Role in tissue factor expression. Thromb Hae-most 2005; 93: 1168-1175.
34. Zavoico GB, Ewenstein BM, Schafer AI, Pober JS. IL-1 and related cytokines enhance thrombin-stimulated PGI2 production in cultured endothelial cells without affecting thrombin-stimulated von Willebrand factor secretion or platelet-activating factor biosynthesis. J Immunol 1989; 142: 3993-3999.
35. Wagner DD, Bonfanti R. von Willebrand factor and the en-dothelium. Mayo Clin Proc 1991; 66: 621-627.
36. Ribes JA, Francis CW, Wagner DD. Fibrin induces release of von Willebrand factor from endothelial cells. J Clin Invest 1987; 79: 117-123.
37. Hattori R, Hamilton KK, McEver RP, Sims PJ. Complement C5b-9 stimulates von Willebrand factor secretion from human endothelium. Circulation 1987; 78 (Suppl): II-117 (Abstract).
38. Paleolog EM, Crossman DC, McVey JH, Pearson JD. Differential regulation by cytokines of constitutive and stimulated secretion of von Willebrand factor from endothelial cells. Blood 1990; 75: 688-695.
39. Penny WF, Weinstein M, Salzman EW, Ware JA. Correlation of circulating von Willebrand factor levels with cardiovascular hemodynamics. Circulation 1991; 83: 1630-1636.
40. Dimopoulos K, Inuzuka R, Goletto S, Giannakoulas G, Swan L, Wort SJ, et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 2010; 121: 20-25.